INTRODUCTION
============

Cis-diamminedichloroplatinum(II)(cisplatin) is administered at doses of 50--100mg/m^2^ in conjunction with intravenous hydration. Split dose is also administered to reduce the toxicities. This article report a 59-year-old man who received a massive cisplatin overdose 300 mg/m^2^ with hydration and managed by plasmapheresis and GM-CSF and who fully recovered from toxicities.

CASE REPORT
===========

A 59 year-old-man with Stage III esophageal squamous cell carcinoma was treated with neoadjuvant 5-Fluorouracil(5-FU) and cisplatin 3 cycles followed by radiotherapy in another hospital. He achieved partial remission. Then disease progression was noted 3 months later.

Chemotherapy with 5-FU 1000mg/m^2^ D~1--5~ and cisplatin 100mg/m^2^ in 5 divided daily doses was reinstituted, but accidentally cisplatin was ordered to be administered daily for 5 days.

On day 3, he began to experience protracted nausea and vomiting, visual dimness and visual hallucination was noted with somnolence and general weakness. After reviewing the drug chart, we found cisplatin was given at 100mg/m^2^ daily for 3 days instead of given in 5 divided daily dose i. e. 20mg/m^2^ daily for 5 days.

We also noted diminished vision but ophthalmoscopic examination showed normal fundus and no papilledema. There was peripheral neuropathy.

On day 4, GM-CSF 250ug/m^2^(400ug) was started.

On day 6, Ccr was 21.4ml/min, aspartate transaminase/alanine transaminase(AST/ALT) were 1127/663 U/L, respectively. Plasmapheresis was initiated in an effort to remove platinum from the patient.

On day 15, leukocyte count was 1700/mm^3^ (granulocyte 63%), fever was sustained and third generation cephalosporin and aminoglycoside were started.

On day 16, septic thrombophlebitis of left forearm was noted and blood culture revealed the growth of Staphylococcus auricularis.

On day 22, agranulocytosis(WBC 600/mm^3^, with no granulocyte) was noted but renal failure and septic condition were restored slowly and swallowing difficulty was also subsided and he was able to swallow solid food without any difficulty, and esophagogram showed good passage of barium meal compared to that of before the chemotherapy. Renal failure was also recovered completely and hearing loss was, too.

METHODS
=======

Measurement of Platinum Concentration
-------------------------------------

Platinum concentrations are measured by flameless Zeeman atomic absorption Spectrophotometry^[@b1-kjim-10-2-150-12]^ by Varian, Spectra AA 300, Sunkyung Industry, Suwon, KyungKiDo.

Samples were obtained from blood, urine and postpheresis plasma. Blood samples were collected in heparinized or acid citrate dextrose tubules, spun in clinical centrifuge within 10 minutes of collection, immediately separated as plasma samples and sent for analysis.

RESULTS
=======

Removal of Cisplatin from the Patient
-------------------------------------

Cisplatin rapidly forms bifunctional cross-links with any nucleophilic molecule, so nucleophilic sulfur thiols can inactivate cisplatin and thus act as chemoprotectants^[@b2-kjim-10-2-150-12]^. But, intracellular thiol, glutathion cannot be available to bind with cisplatin which binds to target sites on proteins and DNA. Exogenously administered thiols could not be effective.

In a previous case^[@b3-kjim-10-2-150-12]^, dialysis was ineffective in lowering plasma platinum concentration because platinum binds to plasma protein very rapidly.

Chu et al proved the effectiveness of plasmapheresis in lowering the plasma platinum concentration^[@b4-kjim-10-2-150-12]^. In this case, the overdosing of cisplatin was found 7 days earlier than Chu\'s case found on day 10.

The patient was treated with plasmapheresis, which proved to be effective in lowering the plasma platinum concentration([Table 1](#t1-kjim-10-2-150-12){ref-type="table"} and [Fig. 1](#f1-kjim-10-2-150-12){ref-type="fig"}).

From day 6 through 9, the patient received plasmapheresis 4 times and the plasma platinum concentration decreased from 2979ng/ml to 430ng/ml and he became very alert and did not have nausea and vomiting, but plasma platinum concentration increased to 834ng/ml on day 11 ([Table 1](#t1-kjim-10-2-150-12){ref-type="table"}). Although cisplatin rapidly became protein bound, this result suggests that there was a pool of exchangeable cisplatin that could move onto new plasma protein binding sites. Thus plasmapheresis was continued through day 16, a total of 10 times. Then the plasma platinum concentration gradually declined. Significant amounts of platinum were excreted in the urine in the setting of the patients non-oliguric renal failure. Thus urine output was increased by careful intravenous hydration([Fig. 4](#f4-kjim-10-2-150-12){ref-type="fig"}).

[Figure 4](#f4-kjim-10-2-150-12){ref-type="fig"} shows the effect of urine volume on platinum clearance and platinum clearance increased linearly with urine volume(r=0.0496 by linear regression).

DISCUSSION
==========

Cisplatin toxicities were severe emesis, myelosuppression, nephrotoxicity and ototoxicity which are seen even in patients receiving usual doses. Others are central neurotoxicity, visual loss and hepatic toxicity which were unusual and probably caused by the magnitude of the overdose.

The severe myelosuppression was complicated by life-threatening sepsis. Thus GM-CSF was instituted 1 day after the stopping of cisplatin. Even though GM-CSF was administered at the earliest possible, nadir leukocyte count was 600/mm^3^ without granulocyte on day 22, and since then recovered fully on day 33.

The most serious and usually dose limiting toxicity of cisplatin is renal. This toxicity is manifested clinically by elevated BUN and creatinine, is cumulative with continued cisplatin exposure and is potentiated by other nephrotoxins^[@b5-kjim-10-2-150-12]^.

Non-oliguric acute renal failure was developed. The creatinine clearance (Ccr) was 21.4ml/min on day 6 and decreased to 8.3ml/min on day 13, but slowly recovered without hemodialysis, so Ccr was 36.6ml/min on day 34. High fluid intake with forced diuresis can reduce the incidence and severity of the renal toxicity^[@b6-kjim-10-2-150-12]^.

Systemic administration of thiols can reduce renal toxicity of cisplatin in animal models, and in clinical trial systemic diethyldithiodicarbamate appeared to reduce nephrotoxicity without affecting ototoxicity or myelosupression^[@b7-kjim-10-2-150-12]^. In this case, N-acetylcystein(Muteran^®^) and mesna were also administered with uncertain efficacy 2 days after cisplatin overdose.

Even though cisplatin induced deafness is seen at conventional doses, it is more pronounced in elderly patients^[@b8-kjim-10-2-150-12]^. This case had transient auditory dimness, but fully recovered.

Ototoxicity is characterized by tinnitus and hearing loss^[@b9-kjim-10-2-150-12]^. The hearing loss is usually in the high frequency range, 4000--8000Hz, but may occur in the lower ranges, which include the speech frequency^[@b10-kjim-10-2-150-12]^. Since the higher frequencies are usually involved, the hearing loss may not be symptomatic. Vestibular toxicity does not usually occur, but can be seen^[@b11-kjim-10-2-150-12]^.

The neurotoxicity, seen with the administration of cisplatin, consists principally of peripheral neuropathy involving both the upper and lower extremities with paresthesias, weakness, tremors and loss of taste^[@b12-kjim-10-2-150-12]^. Seizure and leukoencephalopathy have also been described^[@b13-kjim-10-2-150-12]^. Central nervous system toxicities were visual hallucination, somnolence without seizure on day 3, and peripheral neuropathy was also noted because of previously received cisplatin.

The neurotoxicity has become the dose limiting toxicity of cisplatin^[@b14-kjim-10-2-150-12]^. An interesting observation is that treatment of animals with an ACTH analogue will prevent neurotoxicity from cisplatin, and will facilitate the recovery of established neurotoxicity^[@b15-kjim-10-2-150-12]^, but does not interfere with the antitumor effect of the agent.

Loss of vision was reversible. After 1 month, visual acuity was recovered. Visual toxicity after high dose(200mg/m^2^) cisplatin therapy has been reported previously^[@b16-kjim-10-2-150-12]^.

Visual evoked potentials were normal, and loss of vision primarily was attributable to retinal damage, leading to blurred vision and altered color perception.

Abnormal elevation of transaminase and prothrombin time and partial thromboplastin time was noted. The peak abnormalities were on day 6 and resolved by day 9. The abnormalities in clotting times may have been the result of liver dysfunction and concomitant impaired synthesis of clotting proteins, but also could have been a direct effect of cisplatin binding to the clotting proteins.

Although protein bound platinum is less reactive than the free form, there appeared to be an exchangeable pool of platinum. Chu et al^[@b4-kjim-10-2-150-12]^ observed that clotted blood has low plasma platinum concentration and gradually increased when plasmapheresis was not given, and continued cellular response to cisplatin was measured by a markedly decreased level of XPE binding factor in extractable peripheral blood lymphocytes and supported the presence of an exchangeable pool of platinum.

After most of the cisplatin has become protein bound, high plasma platinum concentration might be capable of exerting biological effects.

As Chu et al suggested, enhancing the clearance of platinum by removing platinum from an exchangeable pool, that was capable of producing additional toxicity, was beneficial to improve the toxicities.

In this case, early trial of plasmapheresis was very effective and shortened the period of non-oliguric renal failure without dialysis. Cisplatin poisoning with 200 mg/m^2^ and 480mg/m^2^ with hydration managed by hemodialysis for renal failure were reported^[@b3-kjim-10-2-150-12],[@b17-kjim-10-2-150-12]^. But hemodialysis was ineffective in lowering the plasma platinum concentration.

Chu et al first treated cisplatin 280 mg/m^2^ overdose and also reported that the use of the growth factor GM-CSF appeared to be safe in attempting to shorten the period of myelosuppression, despite the continued presence of a significant level of cisplatin^[@b4-kjim-10-2-150-12]^.

We report the first case in Korea for cisplatin poisoning successfully managed by plasmapheresis in lowering the plasma platinum concentration.

The Bristol-Myers Squibb spontaneous Adverse Drug Reaction Reporting System reported the three types of dosing errors to have caused the cisplatin overdoses^[@b18-kjim-10-2-150-12]^.

\(1\) Mistaking dosing orders when they are written as the total dosage divided over a period of several days; (2) administering cisplatin when the patient was to have received carboplatin; (3) writing the wrong cisplatin dose.

It recommended that to minimize the possibility of error, the following procedures should be considered^19)^: (1) Always write for the intended daily dose of cisplatin rather than the total dose over a period of time; (2) the institution of an alerting system for orders of cisplatin exceeding 120mg/m^2^ per course.

This case illustrates the need for careful monitoring during administration of any cytotoxic agents and shows that errors can occur, even in a center experienced in the use of high-dose cisplatin. It also suggests that early trial of plasmapheresis can ameliorate the fatal toxicities of cisplatin overdose.

We would like to thank Mr. Cho, Yong Back of Sunkyung Industry Research Center for his assistance in measuring plasma platinum concentration.
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###### 

Concentration of Platinum in Plasma, Urinary Excretion and Removal by Plasmapheresis

  Day   Plasma (ng/ml)   Urine Pt (ng/ml)   Urine Vol. (ml)   Pt excreted (*μ*g/day)   Pheresis Pt (ng/ml)   Pheresis Vol. (ml)   Pt Removed (*μ*g)   Ccr[^\*^](#tfn2-kjim-10-2-150-12){ref-type="table-fn"} (ml/mn)
  ----- ---------------- ------------------ ----------------- ------------------------ --------------------- -------------------- ------------------- ----------------------------------------------------------------
  6     2979                                4200                                       2350                                                           21.4
  7     2304                                5140                                       730                                                            18.3
  8     1360                                4000                                       479                   3600                 1724                13.0
  9     961              868                5200              4514                     430                   3750                 1613                12.8
  10    834              816                4155              3390                                                                                    12.8
  11                                        4250                                       358                   3570                 1285                8.4
  12    735              633                4900              2690                     228                                                            8.3
  13    402                                                                            225                                                            
  14    390                                                                            216                                                            15.1
  15    387                                                                            203                                                            16.0
  16    279                                                                                                                                           18.8
  17    251                                                                                                                                           15.7
  18    192                                                                                                                                           19.7
  19    240                                                                                                                                           19.7
  20    228                                                                                                                                           24.0
  21    185                                                                                                                                           
  29    134              415                4270              1772                                                                                    
  30    134              345                4650              1604                                                                                    
  31    129              227                4150              942                                                                                     
  32    58                                                                                                                                            
  34    134              268                3200              858                                                                                     36.6

Pt: Platinum

Ccr = Bw × (140-age)/72 × serum Cr(mg/dl)
